May 10, 2021

Calyx Welcomes Catalyst to the ACTIVATE CRO Partnership Program

Synergistic offerings deliver successful early-phase oncology clinical trials.

Nottingham, UK – May 10, 2021 — Calyx, the eClinical solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that Catalyst Clinical Research will enter into a partnership with Calyx to leverage Calyx’s Medical Imaging solution for their customers’ oncology trials.

Calyx Chief Commercial Officer, John Blakeley,  looks forward to supporting Catalyst’s knowledgeable, experienced team with a proven imaging solution as they execute complex oncology trials for their biotech clients.

A leading provider of clinical research services, Catalyst Clinical Research’s full-service, niche oncology CRO solution is focused on next-generation cancer therapies. Catalyst Oncology offers skilled management of immuno-oncology and targeted therapies, as well as expert oversight of complex study designs to deliver customized clinical research solutions exclusively for the biotech market.

“We see a lot of synergies between Calyx’s expertise in medical imaging, particularly in early-phase oncology development, and Catalyst Oncology’s clinical development services for the advancement of new cancer treatments,” said Andrew Zupnick, PhD, Vice President of Oncology Drug Development at Catalyst. “We’re pleased to form a relationship through their CRO partnership program and look forward to working together as we help our customers bring novel therapies to cancer patients in need.”

The ACTIVATE Solutions for CRO Partners program is designed to provide close alignment between Calyx and its CRO partners. By participating in the ACTIVATE CRO program, Catalyst can better meet the imaging needs of their clients and help accelerate oncology trial execution and data collection, ultimately delivering more customer value.

“Catalyst is at the forefront in delivering customized services that meet the evolving needs and unexpected changes inherent in oncology clinical development,” said John Blakeley, Chief Commercial Officer at Calyx. “We’re delighted to welcome them to our partnership network and to support their knowledgeable, experienced team with a proven imaging solution as they execute complex oncology trials for their biotech clients.”

Click here for more information on the Calyx ACTIVATE Solutions for CRO Partners program.

About Calyx

Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations (CROs), Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market every day.

Medical Imaging | IRT | CTMS | EDC | RIM

Take your trials further, faster at calyx.ai, LinkedIn, Twitter, or Facebook.

Media Contact:

Christine Tobin | Christine.Tobin@calyx.ai |+1 412-628-8598


Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

  • This field is for validation purposes and should be left unchanged.